



EASD 2026
28 September
02 October
Milan
Italy



Co-formulation of ASC36 and ASC35, Once-Monthly Amylin Receptor Agonist and GLP-1R/GIPR Agonist, Demonstrated Superior Weight Loss to Eloralintide/Tirzepatide Combo in DIO Rats

Conclusion

- **ASC36 is a once-monthly to once-quarterly next-generation amylin receptor agonist peptide.**
- **ASC35 is a once-monthly to once-quarterly next-generation GLP-1R/GIPR agonist peptide.**
- **ASC36_35 co-formulation is designed for the treatment of obesity and chronic weight management.**
- **ASC36_35 co-formulation demonstrates observed $T_{1/2}$ of 33 days for ASC36 and 30 days for ASC35, respectively in NHPs, supporting once-monthly to once-quarterly dosing in humans.**



Jinzi Jason Wu
Chengfei Wu

Ascletis Pharma (China) Co., Limited, Hong Kong

Disclosure: Dr. Jinzi Jason Wu is an employee of Ascletis Pharma (China) Co., Limited, Hong Kong



ASC36 and ASC35 Monotherapy in DIO models

Study 1: ASC36 vs Petrelintide in DIO Rats





91% increase than Petrelintide

Study 2: ASC36 vs Eloralintide in DIO Rats



32% increase than Eloralintide


Study 3: ASC35 vs Tirzepatide in DIO mouse



71% increase than Tirzepatide

Weight Loss of ASC36_35 Co-formulation in DIO Rats

Study 1






ASC36_35 co-formulation demonstrates additive food intake suppression and achieves 39% greater body weight reduction than ASC35 monotherapy

Note:
 1. HFD: High Fat Diet
 2. SQ: Subcutaneous(ly)
 3. Q2D: Every other day

Weight Loss of ASC36_35 Co-formulation in DIO Rats

Study 2



- DIO rat, Vehicle (SQ, Q2D)
- DIO rat, Eloralintide_Tirzepatide co-formulation (5 nmol/kg/ 8 nmol/kg, SQ, Q2D)
- DIO rat, MET-233i_Tirzepatide co-formulation (5 nmol/kg/ 8 nmol/kg, SQ, Q2D)
- DIO rat, ASC36_35 co-formulation (5 nmol/kg/ 8 nmol/kg, SQ, Q2D)
- DIO rat, Vehicle (SQ, Q2D)
- DIO rat, Eloralintide_Tirzepatide co-formulation (5 nmol/kg/ 8 nmol/kg, SQ, Q2D)
- DIO rat, MET-233i_Tirzepatide co-formulation (5 nmol/kg/ 8 nmol/kg, SQ, Q2D)
- DIO rat, ASC36_35 co-formulation (5 nmol/kg/ 8 nmol/kg, SQ, Q2D)

Note:
1. HFD: High Fat Diet
2. SQ: Subcutaneous(ly)
3. Q2D: Every other day

ASC36_35 co-formulation exhibits an additional 98% greater weight loss than eloralintide /tirzepatide co-formulation

Weight Loss of ASC36_35 Co-formulation in NHPs

Study 3




Day 1

Group	Dose level (mg/kg) ASC36_35	Con. (mg/mL) ASC36_35	Volume (mL/kg)
G1 Vehicle Control	0	0	0.1
G2 Low Dose	0.001/0.01	0.01/0.1	0.1
G3 Mid Dose	0.003/0.03	0.03/0.3	0.1
G4 High Dose	0.005/0.05	0.05/0.5	0.1

Day 8 & Day 15


Group	Dose level (mg/kg) ASC36_35	Con. (mg/mL) ASC36_35	Volume (mL/kg)
G1 Vehicle Control	0	0	0.1
G2 Low Dose	0.003/0.03	0.03/0.3	0.1
G3 Mid Dose	0.01/0.1	0.1/1	0.1
G4 High Dose	0.02/0.2	0.2/2	0.1

Male cynomolgus monkeys body weight changes (N=5, Mean±SEM)



■ Vehicle control
 ■ ASC36_35 co-formulation: Low dose
 ■ ASC36_35 co-formulation: Middle dose
 ■ ASC36_35 co-formulation: High dose


Female cynomolgus monkeys body weight changes (N=5, Mean±SEM)



■ Vehicle control
 ■ ASC36_35 co-formulation: Low dose
 ■ ASC36_35 co-formulation: Middle dose
 ■ ASC36_35 co-formulation: High dose

ASC36_35 co-formulation demonstrates dose-dependent weight loss in NHPs

Fibrillation study




- Cagrilintide in pH7.5 HEPES buffer
- ASC36_35 co-formulation (2.5 mg/mL / 5 mg/mL) in solution197, pH 7.0 ± 0.5, 25°C
- ASC36_35 co-formulation (2 mg/mL / 10 mg/mL) in solution197, pH 7.0 ± 0.5, 25°C
- ASC36_35 co-formulation (2.5 mg/mL / 5 mg/mL) in solution260, pH 7.0 ± 0.5, 25°C
- ASC36_35 co-formulation (8 mg/mL / 40 mg/mL) in solution260, pH 7.0 ± 0.5, 25°C
- ASC36_35 co-formulation (2.5 mg/mL / 5 mg/mL) in solution314, pH 7.0 ± 0.5, 25°C
- ASC36_35 co-formulation (8 mg/mL / 40 mg/mL) in solution314, pH 4.0 ± 0.5, 25°C

ASC36_35 co-formulations have excellent chemical and physical stability with no aggregation or precipitation caused by fibrillation at neutral pH.

PK Profile in NHPs

ASC36_35 co-formulation



- ASC36_35 co-formulation in solution332 (0.25 / 0.5 mg/kg): analyte ASC35
- ASC36_35 co-formulation in solution332 (0.25 / 0.5 mg/kg): analyte ASC36

Treatment	Dose Route	Analyte	Observed T _{1/2}
			(h)
ASC36_35 in solution332 (0.25 mg/kg+ 0.5 mg/kg)	SC	ASC36	781
		ASC35	721

ASC36_35 co-formulation demonstrates observed T_{1/2} of 781 h (33 days) for ASC36 and 721 h (30 days) for ASC35, respectively in NHPs, supporting once-monthly to once-quarterly dosing in humans.

ASC36_35 Co-formulation Summary

- **ASC36 is a once-monthly to once-quarterly next-generation amylin receptor agonist peptide. ASC35 is a once-monthly to once-quarterly GLP-1R/GIPR agonist peptide.**
- **ASC36_35 co-formulation demonstrates marked body weight reduction in DIO rats and NHPs.**
- **ASC36_35 co-formulation has excellent chemical and physical stability with no aggregation or precipitation caused by fibrillation at neutral pH.**
- **ASC36_35 co-formulation demonstrates observed $T_{1/2}$ of 781 h (33 days) for ASC36 and 721 h (30 days) for ASC35, respectively in NHPs, supporting once-monthly to once-quarterly dosing in humans.**

E-poster




Co-formulation of ASC36 and ASC35, Once-Monthly Amylin Receptor Agonist and GLP-1R/GIPR Agonist, Demonstrated Superior Weight Loss to Eloralintide/Tirzepatide Combo in DIO Rats

Jinzi Jason Wu and Chengfei Wu
Ascletris Pharma (China) Co., Limited, Hong Kong


Introduction
Fixed-dose combination of ASC36 and ASC35 (ASC36_35 co-formulation) is a co-formulation of ASC36, a once-monthly next-generation amylin receptor agonist peptide, and ASC35, a once-monthly next-generation GLP-1R/GIPR agonist peptide, developed in-house utilizing Ultra-Long-Acting Platform (ULAP) technology. ASC36_35 co-formulation is designed for the treatment of obesity and chronic weight management. ASC36 and ASC35 demonstrates potent *in vitro* activity and robust *in vivo* pharmacodynamic efficacy in reducing body weight. ASC36_35 co-formulation shows robust weight-reducing efficacy in DIO rats and cynomolgus monkeys, across both rodent and non-human primate (NHP) models. ASC36_35 co-formulation has excellent chemical and physical stability with no aggregation or precipitation caused by fibrillation at neutral pH. In NHPs, ASC36_35 co-formulation demonstrates observed $T_{1/2}$ of 781 h (33 days) for ASC36 and 721 h (30 days) for ASC35, supporting once-monthly to once-quarterly dosing in humans.

Methods and Results

ASC36_35 Co-formulation Efficacy Studies in DIO Rats and Monkeys



Fibrillation Study and PK Profile in NHPs



Conclusion

- ASC36 is a once-monthly to once-quarterly next-generation amylin receptor agonist peptide. ASC35 is a once-monthly to once-quarterly GLP-1R/GIPR agonist peptide.
- ASC36_35 co-formulation demonstrates marked body weight reduction in DIO rats and NHPs.
- ASC36_35 co-formulation has excellent chemical and physical stability with no aggregation or precipitation caused by fibrillation at neutral pH.
- ASC36_35 co-formulation demonstrates observed $T_{1/2}$ of 781 h (33 days) for ASC36 and 721 h (30 days) for ASC35, respectively in NHPs, supporting once-monthly to once-quarterly dosing in humans.

Disclosure:
Jinzi Jason Wu, Employee of Ascletris Pharma (China) Co., Limited;
Chengfei Wu, Employee of an affiliate of Ascletris Pharma (China) Co., Limited.
For more details, please visit our official website: <https://www.ascletris.com>

